• Clinical Trials - Ovarian Cancer

    Study Objective Contact
    A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Niraparib in patients with Advanced, Relapsed, High Grade Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer who have Received Three or Four Previous Chemotherapy Regimens [LCID Study Number: 2015-022] To evaluate the safety and efficacy of investigational medication, niraparib, in patients with ovarian cancer, fallopian tube cancer or peritoneal cancer who have received at least three previous chemotherapy regimens. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Joyce E. Pelletier.
    A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib versus Placebo in Patients with Platinum Sensitive Ovarian Cancer [LCID Study Number: 2014-024] NOVA is a maintenance trial for women with ovarian cancer, aged 18 and older, to find out if niraparib (a PARP inhibitor) can help delay worsening of ovarian cancer among patients who had a good response to previous treatment with a platinum-type chemotherapy drug (i.e. cisplatin, carboplatin). Niraparib will be compared to placebo and patients will be randomized so that 2 out of 3 patients will take niraparib and 1 out of 3 will take placebo. This study is designed with the hope of preventing worsening of the cancer after another treatment has caused the cancer to improve. This study is closed to accrual and no longer accepting new patients. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Joyce E. Pelletier.
    GOG 0186J: A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC#673089) Plus Pazopanib (NSC# 737754) (IND# 75648) versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma [LCID Study Number: 2012-020] The purpose of this study is to compare the effectiveness of the combination of the drugs paclitaxel and pazopanib to the combination of paclitaxel and placebo (sugar pill) in treating ovarian, peritoneal and fallopian tube cancer and to determine the types and severity of side effects caused by treatment with these drug combinations. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Donna Cossar.
    GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? [LCID Study Number: 2015-037] The purpose of this study is to find out if a change in diet and exercise in women who have completed treatment for stage II, III, or IV ovarian, fallopian tube or primary peritoneal cancer has an effect on the length of cancer free time following initial treatment. Some studies suggest diet and exercise may improve survival for cancer patients, but no studies have been done to show if changes in diet and exercise can have an effect on cancer returning. Other goals include finding out if the changes in diet and exercise will improve overall quality of life and ability to be physically active. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Amanda M. Pietras.
    GOG-0252: A Phase III Clinical Trial Of Bevacizumab With IV Versus IP Chemotherapy In Ovarian, Fallopian Tube And Primary Peritoneal Carcinoma NCI-Supplied Agent(S): Bevacizumab (NSC #704865, IND #7921) [LCID Study Number: 2010-017] This study will compare IV chemotherapy with two different IP treatment plans (regimens) to determine if there is a survival benefit. This study will also collect information on side effects and possible complications of IP administration, using questionnaires. This study will ask patients how they feel during treatment to assess the risks and benefits of each treatment from the patient’s perspective. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Donna Cossar,
    Sherry G. Heldt, RN.
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.
    NRG-GY004 A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer [LCID Study Number: 2016-069CIRB] This randomized phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine hydrochloride, and pegylated liposomal doxorubicin hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether olaparib or cediranib maleate and olaparib is more effective than standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Principal Investigator(s):
    Neela Natarajan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Julie Roache.